Molecular docking, Synthesis, Computational Studies and In-vitro evaluation of 7-Substituted-2-Pyrimidinyl Chromen-4-one derivatives

Author:

Naseer Arif1,Ratra Shami1,Kumar Umesh2,Singh Thakur Gurjeet3

Affiliation:

1. School of Pharmacy, Adarsh Vijendra Institute of Pharmaceutical Sciences (AVIPS), Shobhit University, Gangoh, Saharanpur, India – 247341.

2. School of Pharmaceutical Sciences, Shri Venkateshwara University, Gajraula, Amroha, India – 244236.

3. Chitkara College of Pharmacy, Chitkara University, Punjab, 140401, India.

Abstract

Design and synthesis of 7-substituted-2-pyrimidinyl chromen-4-one derivatives as selective Cyclooxygenase-2 inhibitors (1) Method: The compounds were designed using molecular hybridization technique, docking studies was performed using Autodock Vina, compounds having higher affinity than celecoxib were selected and synthesized followed by spectral characterization. The synthesized derivatives (1a, 1b, 2-9) were subjected to ADMET and PASS prediction studies. In vitro antioxidant potential was assayed by DPPH method and in vitro anti-inflammatory activity was assessed by protein denaturation method. (2)Result: Compounds under study have been found to exhibit good to moderate anti-inflammatory activity. Among these, compounds 1a, 1b and 4 exhibited maximum anti-inflammatory activity which is comparable to the activity of Diclofenac sodium. Compound 1a and 4 are found to be the most potent antioxidant with a remarkable IC50 value of 6.99 and 7.25 respectively, which is a little less than the standard drug, ascorbic acid, (IC50=6.94). In addition, a comparative examination of calculated Lipinski’s parameters reveals that all the compounds have the tendency to be orally bioavailable. PASS studies also show that certain compounds also have higher probability of anti-neoplastic activity. (3) Conclusion: Based on the outcomes, compounds 1a, 1b, 3, 4 and 8 can act as novel leads for the development of COX-2 inhibitors showing potent anti-inflammatory and antioxidant activity which can have lesser GI side effects and can be used in chronic disorders.

Publisher

A and V Publications

Subject

Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3